PHS
AERI

PFM Health Sciences’s Aerie Pharmaceuticals AERI Stock Holding History

PFM Health Sciences’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-699,531
Closed -$5.25M – 95
2022
Q2 		$5.25M Sell
699,531
-389,035
-36% -$2.74M 0.2% 74
2022
Q1 		$9.91M Hold
1,088,566
– – 0.37% 53
2021
Q4 		$7.64M Sell
1,088,566
-1,094,118
-50% -$11.4M 0.26% 59
2021
Q3 		$24.9M Hold
2,182,684
– – 0.73% 47
2021
Q2 		$34.9M Buy
2,182,684
+115,000
+6% +$1.97M 1.1% 35
2021
Q1 		$37M Sell
2,067,684
-159,927
-7% -$2.76M 1.13% 31
2020
Q4 		$30.1M Hold
2,227,611
– – 1.06% 36
2020
Q3 		$26.2M Sell
2,227,611
-46,609
-2% -$568K 1.21% 32
2020
Q2 		$33.6M Sell
2,274,220
-254,056
-10% -$3.76M 1.74% 20
2020
Q1 		$34.1M Buy
2,528,276
+114,812
+5% +$2.18M 2.8% 13
2019
Q4 		$58.3M Buy
2,413,464
+582,540
+32% +$12.1M 2.78% 11
2019
Q3 		$35.2M Buy
+1,830,924
New +$41.9M 1.04% 35
2019
Q1 		– Sell
-1,893,935
Closed -$68.4M – 122
2018
Q4 		$68.4M Sell
1,893,935
-364,508
-16% -$17.1M 1.82% 23
2018
Q3 		$139M Sell
2,258,443
-461,775
-17% -$29.7M 2.04% 7
2018
Q2 		$184M Sell
2,720,218
-112,785
-4% -$6.31M 2.88% 5
2018
Q1 		$154M Buy
2,833,003
+225,792
+9% +$12.6M 3.12% 5
2017
Q4 		$156M Buy
2,607,211
+193,750
+8% +$11.7M 3.69% 3
2017
Q3 		$117M Buy
2,413,461
+665,421
+38% +$36.3M 2.3% 7
2017
Q2 		$91.9M Buy
1,748,040
+454,911
+35% +$21.2M 2.47% 8
2017
Q1 		$58.6M Sell
1,293,129
-142,626
-10% -$6.36M 1.47% 26
2016
Q4 		$54.3M Sell
1,435,755
-530,662
-27% -$20.1M 1.53% 23
2016
Q3 		$74.2M Sell
1,966,417
-375,223
-16% -$8.27M 2.17% 11
2016
Q2 		$41.2M Sell
2,341,640
-39,495
-2% -$639K 1.24% 37
2016
Q1 		$29M Buy
2,381,135
+6,338
+0.3% +$100K 0.89% 37
2015
Q4 		$57.8M Buy
2,374,797
+156,599
+7% +$3.65M 1.76% 23
2015
Q3 		$39.4M Buy
2,218,198
+366,634
+20% +$6.64M 1.11% 34
2015
Q2 		$32.7M Buy
1,851,564
+1,616,119
+686% +$29.6M 0.83% 43
2015
Q1 		$7.38M Buy
+235,445
New +$6.82M 0.2% 76

Other funds holding AERI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFM Health Sciences's AERI Position: Q3 2022 in Review

PFM Health Sciences sold out of Aerie Pharmaceuticals (AERI) in Q3 2022, closing a stake of 699,531 shares — an estimated $5.25M sold.

PFM Health Sciences first reported a position in AERI in Q1 2015 and held it in 28 quarters. The position peaked at $184M in Q2 2018. 156 funds tracked by Wall St. Rank hold AERI as of Q3 2022.

  • PFM Health Sciences reported no remaining Aerie Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • PFM Health Sciences sold 699,531 Aerie Pharmaceuticals shares in Q3 2022, an estimated $5.25M.
  • PFM Health Sciences first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 28 quarters.
  • PFM Health Sciences's Aerie Pharmaceuticals position peaked at $184M in Q2 2018.
  • 156 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2022.

Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.